Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 20/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 11/20 | 1.00 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.55 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.55 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.55 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.55 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14645446 | 0.88 | HDAC4 (1.00) | HDAC4HDAC6HDAC1HDAC3HDAC7 | |
| SCHEMBL21899986 | 0.84 | HDAC4 (0.72) | HDAC4HDAC6HDAC1HDAC3HDAC7 | |
| SCHEMBL21543794 | 0.84 | HDAC4 (0.72) | HDAC4HDAC6HDAC1HDAC3HDAC7 | |
| SCHEMBL21903425 | 0.84 | HDAC4 (0.72) | HDAC4HDAC6HDAC1HDAC5 | |
| SCHEMBL21903445 | 0.84 | HDAC6 (0.72) | HDAC4HDAC6HDAC1HDAC5 | |
| SCHEMBL21900018 | 0.83 | HDAC4 (0.71) | HDAC4HDAC6HDAC1HDAC3HDAC7 | |
| SCHEMBL21900019 | 0.83 | HDAC4 (0.71) | HDAC4HDAC6HDAC1HDAC3HDAC7 | |
| SCHEMBL20593615 | 0.83 | HDAC4 (0.71) | HDAC4HDAC6HDAC1HDAC3HDAC7 | |
| SCHEMBL20446195 | 0.83 | HDAC4 (0.71) | HDAC4HDAC6HDAC1HDAC5 | |
| SCHEMBL19030803 | 0.83 | HDAC4 (0.76) | HDAC4HDAC6HDAC1HDAC3HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11154060-B2 | Microbiocidal oxadiazole derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2021-10-26 | — | — | US | claimed |
| US-20200138027-A1 | MICROBIOCIDAL OXADIAZOLE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2020-05-07 | — | — | US | claimed |
| EP-3458446-A1 | MICROBIOCIDAL OXADIAZOLE DERIVATIVES | Syngenta Participations AG (CH) | 2019-03-27 | — | — | EP | claimed |
| WO-2017198852-A1 | MICROBIOCIDAL OXADIAZOLE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2017-11-23 | — | — | WO | claimed |
| EP-2729454-B1 | NOVEL TRIFLUOROMETHYL-OXADIAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2015-09-16 | — | — | EP | claimed |
| US-9056843-B2 | Trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease | NOVARTIS AG (CH) | 2015-06-16 | — | — | US | claimed |
| US-20140142105-A1 | NOVEL TRIFLUOROMETHYL-OXADIAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2014-05-22 | — | — | US | claimed |
| EP-2729454-A1 | NOVEL TRIFLUOROMETHYL-OXADIAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | Novartis AG (CH) | 2014-05-14 | — | — | EP | claimed |
| WO-2013008162-A1 | NOVEL TRIFLUOROMETHYL-OXADIAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2013-01-17 | — | — | WO | claimed |
| US-11154060-B2 | Microbiocidal oxadiazole derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2021-10-26 | — | — | US | disclosed |
| US-11154060-B2 | Microbiocidal oxadiazole derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2021-10-26 | — | — | US | disclosed |
| US-20200138027-A1 | MICROBIOCIDAL OXADIAZOLE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2020-05-07 | — | — | US | disclosed |
| US-20200138027-A1 | MICROBIOCIDAL OXADIAZOLE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2020-05-07 | — | — | US | disclosed |
| EP-3458446-A1 | MICROBIOCIDAL OXADIAZOLE DERIVATIVES | Syngenta Participations AG (CH) | 2019-03-27 | — | — | EP | disclosed |
| US-20140142105-A1 | NOVEL TRIFLUOROMETHYL-OXADIAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2014-05-22 | — | — | US | disclosed |
| US-20140142105-A1 | NOVEL TRIFLUOROMETHYL-OXADIAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2014-05-22 | — | — | US | disclosed |
| US-20140142105-A1 | NOVEL TRIFLUOROMETHYL-OXADIAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2014-05-22 | — | — | US | disclosed |
| EP-2729454-A1 | NOVEL TRIFLUOROMETHYL-OXADIAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | Novartis AG (CH) | 2014-05-14 | — | — | EP | disclosed |
| WO-2013008162-A1 | NOVEL TRIFLUOROMETHYL-OXADIAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2013-01-17 | — | — | WO | disclosed |
| WO-2013008162-A1 | NOVEL TRIFLUOROMETHYL-OXADIAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2013-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140142105-A1 | NOVEL TRIFLUOROMETHYL-OXADIAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | HDAC4, HDAC5, HDAC6 | HDAC4 1/4885HDAC6 3/4885HDAC1 5/4885 |
| US-20200138027-A1 | MICROBIOCIDAL OXADIAZOLE DERIVATIVES | MPO, MSR1, NOX3 | HDAC4 1387/4885HDAC6 564/4885HDAC1 435/4885 |
| US-11154060-B2 | Microbiocidal oxadiazole derivatives | MPO, MSR1, NOX3 | HDAC4 1387/4885HDAC6 564/4885HDAC1 435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.